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We report draft genome sequences of 40Pseudomonas aeruginosa strains, isolated from the sputumof a single cystic fibrosis patient
over eight years. Analyses indicated a correlation betweenmultidrug-resistant phenotypes and population structure.Our data provide
new insights into themechanisms leading to acquisition of antibiotic resistance inP. aeruginosa.
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Pseudomonas aeruginosa is the most pervasive of all recognizedpathogens in the nosocomial environment, causing pulmonary
and bloodstream infection with mortality rates of up to 50% (1).
Multi-drug-resistant (MDR) P. aeruginosa strains are emerging with
increasing frequencyand infectionrateshave tripledover thepast two
decades (2, 3). Some P. aeruginosa strains have been found to be
resistant to nearly all or all antibiotics in clinical use (4).
Cystic fibrosis (CF) patients infected with resistant P. aeruginosa
are exposed to increasedmortality andmorbidity (5, 6) and estimates
indicate that 25 to 45% of adult CF patients are chronically infected
with MDR P. aeruginosa within their airway (7). The bacterium de-
velops MDR phenotypes during its persistence in a CF patient’s air-
way by accumulating pathoadaptive mutations (8). Whole-genome
sequencing (WGS) can help to point out potential molecular mech-
anisms of resistance and has already proved to be able to predict
antimicrobial susceptibility in several pathogens (9, 10). However,
despite the fact that severalWGS studies onP. aeruginosaCF lineages
have been published (11–14), their evolutionary trajectories in rela-
tion to the development of antimicrobial resistance remain mostly
unexplored to date.
To track thepathoadaptive changes leading to thedevelopmentof
MDR in P. aeruginosa during its microevolution in a CF patient’s
airway, we obtained whole-genome sequences of 40 P. aeruginosa
clinical CF strains isolated at Trentino Regional Support CF Centre
(Rovereto, Italy) from the sputum of a single CF patient over an
eight-year period (2007 to 2014). Interestingly, despite a high degree
of genome sequence conservation, isolates evolved toward the acqui-
sition of anMDR phenotype over time.
Bacteriawere grown inLuria-Bertani broth overnight at 37°C in a
shaking incubator. Cells were harvested and genomic DNA was ex-
tracted using the DNeasy blood and tissue kit (Qiagen, Germany)
following the manufacturer’s instructions for Gram-negative bacte-
ria. Genomic DNA libraries were prepared using the Nextera XT
DNA library preparation kit and protocols (Illumina, USA) and se-
quenced on the Illumina MiSeq platform at the Next Generation
Sequencing (NGS)CoreFacilityof theCentre for IntegrativeBiology,
University of Trento. Assembly of draft genomes was carried out us-
ing SPAdes version 3.1.0 (15). To improve the assemblies’ qualities,
raw reads weremapped on the contigs using Bowtie2 v2.2.6 (16) and
contigs with less than three reads mapping and/or with coverage be-
low 1 were removed.
Identification of MLST profiles (sequence types) was per-
formed in silico from de novo assembled genomes usingMLST 1.8
(Table 1) (17).
The average number of contigs per genome was 101 with a
standard deviation of 56. Draft genomes ranged in size from
6,545 kbp to 6,653 kb with a GC content of 66.28% (Table 1).
The N50 of the draft genomes ranged from 30,645 to 378,317 bp
with an average of 179.843 bp (Table 1).
Accession number(s). This whole-genome shotgun project
has been deposited at DDBJ/ENA/GenBank. See Table 1 for acces-
sion numbers of the single genomes. The version described in this
paper is the first one.
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TABLE 1 Draft genome sequences and global statistics of the 40 P. aeruginosa CF isolates
Accession no. Isolate name Yr of isolation Sequence type No. of contigs Genome size (kb) N50 (kb) GC content (%)
MAUO00000000 TNCF_3 2007 390 139 6,636 92 66.28
MAUP00000000 TNCF_4M 2007 390 161 6,630 78 66.29
MAUQ00000000 TNCF_6 2007 390 356 6,618 31 66.28
MAUR00000000 TNCF_7M 2007 390 259 6,623 47 66.28
MAUS00000000 TNCF_10 2007 390 101 6,643 143 66.28
MAUT00000000 TNCF_10M 2007 390 107 6,633 111 66.29
MAZG00000000 TNCF_12 2007 390 102 6,545 177 66.36
MAZI00000000 TNCF_13 2007 390 75 6,637 195 66.27
MAZH00000000 TNCF_14 2007 390 89 6,633 158 66.28
MAKL00000000 TNCF_16 2007 1864 59 6,638 269 66.28
MAZJ00000000 TNCF_23 2007 390 71 6,635 228 66.28
MAZK00000000 TNCF_23M 2007 390 64 6,636 228 66.28
MAKM00000000 TNCF_32 2007 390 67 6,639 229 66.28
MAZL00000000 TNCF_32M 2007 390 138 6,627 93 66.28
MAZM00000000 TNCF_42 2008 390 70 6,639 228 66.28
MAZN00000000 TNCF_42M 2008 390 71 6,640 228 66.28
MAZO00000000 TNCF_49M 2008 390 76 6,635 177 66.29
MAZP00000000 TNCF_68 2010 390 82 6,633 162 66.28
MAZQ00000000 TNCF_69 2010 1863 88 6,639 150 66.28
MAZR00000000 TNCF_76 2010 390 61 6,634 281 66.28
MAZS00000000 TNCF_85 2010 1864 101 6,644 124 66.29
MAZT00000000 TNCF_88M 2010 1864 65 6,636 229 66.28
MAZU00000000 TNCF_101 2011 1864 142 6,653 92 66.28
MAZV00000000 TNCF_105 2011 390 92 6,644 191 66.28
MAZW00000000 TNCF_106 2011 390 77 6,634 205 66.28
MAZX00000000 TNCF_109 2011 390 69 6,634 205 66.28
MAZD00000000 TNCF_130 2012 390 157 6,625 76 66.28
MAZF00000000 TNCF_133 2012 390 82 6,637 154 66.29
MAZE00000000 TNCF_133_1 2012 1864 87 6,641 269 66.28
MAKK00000000 TNCF_151 2013 390 53 6,629 378 66.28
MBMI00000000 TNCF_151M 2013 1864 103 6,636 143 66.28
MBMJ00000000 TNCF_154 2013 390 86 6,635 177 66.28
MBMK00000000 TNCF_155 2013 390 62 6,634 339 66.28
MBML00000000 TNCF_155_1 2013 1923 71 6,635 221 66.28
MBMM00000000 TNCF_165 2013 1923 119 6,634 135 66.28
MBMN00000000 TNCF_167 2013 390 73 6,634 191 66.27
MBMO00000000 TNCF_167_1 2013 390 91 6,628 143 66.28
MBMP00000000 TNCF_174 2014 390 111 6,645 143 66.29
MBMQ00000000 TNCF_175 2014 390 118 6,642 124 66.28
MBMR00000000 TNCF_176 2014 1923 61 6,637 354 66.28
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